NOTICE OF ALLOWANCE - ISSUED
issued
on 05 Nov 2024
Last Applicant/ Owned by
852 WINTER STREET
WALTHAM
MA
02451
Serial Number
98210397 filed on 05th Oct 2023
Registration Number
N/A
Correspondent Address
Norm J. Rich
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
NEMCASGO
Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceutic Read More
Classification Information
Class [044]
Medical, Beauty & Agricultural Services
Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [042]
Computer & Software Services & Scientific Services
Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Therapeutic proteins for use in the manufacture of pharmaceutical preparations
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 98210397
Mark Type
No Service Mark
Attorney Docket Number
No 039079-0110
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 05th Nov 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 10th Sep 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 10th Sep 2024 | PUBLISHED FOR OPPOSITION |
| 21st Aug 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 08th Aug 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 11th Jun 2024 | EXAMINERS AMENDMENT -WRITTEN |
| 11th Jun 2024 | EXAMINERS AMENDMENT E-MAILED |
| 11th Jun 2024 | EXAMINER'S AMENDMENT ENTERED |
| 11th Jun 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 23rd Apr 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |